| 商品名称 | Possia |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Peripheral Vascular Diseases;Acute Coronary Syndrome |
| 通用名/非专利名称 | ticagrelor |
| 活性成分 | ticagrelor |
| 产品号 | EMEA/H/C/002303 |
| 患者安全信息 | No |
| 许可状态 | Withdrawn |
| ATC编码 | B01AC24 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2010/12/03 |
| 上市许可开发者/申请人/持有人 | AstraZeneca AB |
| 人用药物治疗学分组 | Antithrombotic agents |
| 兽用药物治疗学分组 | |
| 欧盟委员会决定日期 | 2012/10/24 |
| 修订号 | 2 |
| 治疗适应症 | Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG). |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2012/10/24 |
| 最后更新日期 | 2013/04/22 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/possia-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/possia |